AGTC

Sue Washer, President and CEO

Oct. 13 | 11:15am | BlueRock Therapeutics Ballroom

Alachua, FL
(NASDAQ: AGTC)

In-person Presentation
Applied Genetic Technologies Corporation (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic, and central nervous system diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with inherited retinal diseases. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia. Its preclinical programs build on AGTC’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology, and CNS disorders. AGTC has entered into strategic partnerships including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.

www.agtc.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions